前列腺癌与前列腺增生的差异基因比较

Differences in Gene Expression between Prostate Cancer and Benign Prostatic Hyperplasia

目的比较前列腺癌（prostate cancer，PCa）和前列腺增生（benign prostatic hyperplasia，BPH）的差异表达基因，试图从基因差异水平为前列腺癌与前列腺增生提供诊疗价值。方法应用Agilent人全基因组表达谱芯片（4。44K）筛选前列腺癌组织和前列腺增生组织中差异表达的基因，并对筛选出的差异基因进行聚类分析、GO和KEGGpathway富集等分析。结果从表达谱结果分析发现，前列腺癌组织与其对照的前列腺增生组织相比，共有327个差异基因（P〈0．05；Foldchange〉2），其中138个基因表达上调。189个基因下调。GO富集分析显示下调的差异基因主要参与T细胞受体合成、整合素介导的细胞黏附过程、B细胞分化过程、树突细胞趋化及迁移作用、免疫突触的形成等。KEGG分析显示差异基因主要参与先天性免疫缺陷、牛磺酸代谢、组氨酸代谢和B细胞受体信号通路等。结论前列腺癌与前列腺增生组织的基因表达芯片结果显示，差异基因主要参与机体的免疫细胞形成过程、介导体内免疫反应异常，或可为前列腺癌的诊治提供新的预测指标和治疗新靶点，同时也为前列腺癌的研究提供了有价值的临床数据。

Objective To compare the differentially expressed genes between prostate cancer and benign prostatic hyperplasia （BPH） in an attempt to provide diagnostic value for prostate canc-er and BPH. Methods Agilent human genome-wide expression profiling microarray （4 44 K） was used to screen differentially expressed genes in prostate cancer and BPH tissues, and the differ-entially expressed genes were analyzed by cluster analysis, GO and KEGG pathway enrichment. Results The expression profiling analysis showed that there were 327 differentially expressed genes in prostate cancer tissues （P 〈 0. 05 ; Fold change 〉 2） compared with those in BPH tissues, of which 138 genes were up-regulated and 189 genes were down-regulated. GO enrichment analysis re-vealed that the down-regulated differential genes were mainly involved in T cell receptor synthesis, integrin-mediated cell adhesion, B cell differentiation, dendritic cell chemotaxis and migration, and formation of immune synapses. KEGG analysis showed that the differential genes were mainly involved in innate immune deficiency, taurine metabolism, histidine metabolism, and B cell re-ceptor signaling pathways. Conclusion Gene expression microarray of prostate cancer and BPH showed that differentially expressed genes are mainly involved in the formation of immune cells and the meditation ofin-vivoimmune responses. Analyses of differentially expressed genes between pros-tate cancer and BPH can provide new predictors and new targets for the diagnosis and treatment of prostate cancer. They also provide valuable clinical data for the study of prostate cancer.